UFT経口投与後の血中および前立腺腫瘍内5-FU濃度の検討

Abstract

前立腺癌11例(前立腺全摘除術4例, TUR-P 7例)を対象として, 術前UFT(600 mg/日, 分3, 5日以上)経口投与後の血清, 尿および組織内FT, 5-FUおよびuracil濃度を測定した.1)UFT服用後検体採取までの時間は, 全摘群で290±60分, TUR-P群では189±32分であり, TUR-P群の方が有意に短かった.2)腫瘍組織内5-FU濃度は全摘群で0.018±0.012 μg/g, TUR-P群で0.024±0.010 μg/gであり, 他臓器癌での値に比べ低値であった.また全摘群で, 腫瘍組織内濃度が0.018±0.012 μg/gであるのに対し, 正常組織内濃度は0.013±0.008 μg/gで, 有意差をみなかった.3)血清中5-FU濃度との比でも同様にそれぞれ2.20, 1.46であり, 両群の間に有意差をみなかった

The serum, urine and tissue concentrations of 1-(2-tetrahydrofuryl)-5-fluorouracil (FT), 5-fluorouracil (5-FU) and uracil were estimated in 11 patients with prostate cancer (4 cases treated by total prostatectomy and 7 cases by transurethral resection (TUR-P) after oral administration of UFT. The concentration of FT, 5-FU and uracil in the tumor tissue (micrograms/g) were 5.920 +/- 5.902, 0.018 +/- 0.012 (T/S; 2.20) and 7.785 +/- 4.151 in 4 patients treated by total prostatectomy and 1.943 +/- 1.355, 0.024 +/- 0.010 (T/S; 1.46) and 4.616 +/- 2.848 in 7 patients treated by transurethral resection of prostate. The concentrations of FT, 5-FU and uracil in the tumor tissue did not increase as compared with those in normal tissue in 4 cases treated by total prostatectomy.